Goldman Sachs Group, Inc. (The) initiated coverage on shares of ZEALAND PHARMA (NASDAQ:ZEAL) in a research note issued to investors on Wednesday, MarketBeat.com reports. The firm issued a buy rating on the stock.

A number of other brokerages also recently issued reports on ZEAL. Needham & Company LLC initiated coverage on shares of ZEALAND PHARMA in a report on Tuesday, September 5th. They issued a buy rating and a $26.00 price target on the stock. Guggenheim initiated coverage on shares of ZEALAND PHARMA in a report on Tuesday, September 5th. They issued a buy rating and a $28.00 price target on the stock. Finally, Morgan Stanley initiated coverage on shares of ZEALAND PHARMA in a report on Tuesday, September 5th. They issued an overweight rating and a $28.00 price target on the stock.

ZEALAND PHARMA (NASDAQ:ZEAL) opened at 19.20 on Wednesday. The company has a 50-day moving average of $18.60 and a 200 day moving average of $18.60. ZEALAND PHARMA has a 12 month low of $16.07 and a 12 month high of $20.37. The stock’s market capitalization is $586.79 million.

COPYRIGHT VIOLATION WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/01/zealand-pharma-zeal-now-covered-by-goldman-sachs-group-inc-the.html.

About ZEALAND PHARMA

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.

Receive News & Stock Ratings for ZEALAND PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA and related stocks with our FREE daily email newsletter.